A novel potential therapy for HSV

Division of Neurosurgery, University of Alabama at Birmingham, Birmingham, Alabama, United States
New England Journal of Medicine (Impact Factor: 55.87). 01/2014; 370(3):273-4. DOI: 10.1056/NEJMe1313982
Source: PubMed


Two medications are licensed in the United States for the treatment of infection with genital herpes simplex virus (HSV): valacyclovir (approved by the Food and Drug Administration in 1995) and famciclovir (approved in 1997). All studied and licensed drugs for HSV infections assessed to date are selective inhibitors of HSV DNA polymerase and act as analogues of nucleoside triphosphate.(1) The report by Wald and colleagues in this issue of the Journal(2) introduces two fundamentally new approaches to the study of medications for the treatment of genital herpes. One approach involves the application of daily quantitative polymerase-chain-reaction (PCR) analysis to define ...

30 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Genital herpes is caused by the herpes simplex virus type 1 or 2 and is regarded as one of the most common sexually transmitted infections (STI) and the main cause of genital ulcer disease (GUD) in the developing world. Antiviral treatment with nucleoside analogues offers clinical benefit to symptomatic individuals with first-episode or primary genital herpes as well as for recurrent herpetic episodes.